Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCRT After ER for Stage I Esophageal Squamous Cell Carcinoma
NCT04275986Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jan 2020
- Primary completion
- Jan 2024
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of nedaplatin, liposomal paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
nedaplatinliposomal paclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04275986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275986.